Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Identification of 5F-Cumyl-PINACA, a Synthetic Cannabinoid, in the Herbal Material Used for Recreational Purposes in the Province of Trieste: Public Health Implications

Author(s): Michela Peruch, Riccardo Addobbati, Martina Padovano, Matteo Scopetti, Monica Concato, Davide Radaelli and Stefano D’Errico*

Volume 24, Issue 6, 2023

Published on: 17 October, 2022

Page: [758 - 765] Pages: 8

DOI: 10.2174/1389201023666220915092609

Price: $65

Abstract

Background: In recent years, the phenomenon of the production and trade of synthetic cannabinoids has grown, becoming a public health issue worldwide. The recent access- to the ED of the hospital of Trieste- of people who complained of episodes of hallucinations, sensation of poisoning, tachycardia, and air hunger following the inhalation of "Che Sballo platinum", have highlighted the need to perform further analysis on the contents of the packet sold as an air freshener, produced in Koper (Slovenia).

Objective: This paper wants to be an alert about the possible consequences on health due to the spreading of “Che Sballo platinum” in the province of Trieste.

Methods: The package contents were analyzed by a multi-target screening method of MRM-IDAEPI experiment. The result was then confirmed, and quantification was achieved via LC-ESI-MS/MS analysis in MRM mode using QTrap 6500 + Sinergy hydro column 100 x 2 mm 1.9 um transitions MRM1 368.3 → 250.0; MRM2 368.3 → 233.0.

Results: The initial screening tested negative for THC and showed positive results for 5F-Cumyl- PINACA. Quantitation result reported dose by the package of 8.5 mg of the compound. Formal notification was sent to the Italian Health Authorities (Notification No. 2021110205).

Conclusion: Consumption of 5F-Cumyl-PINACA results in much more potent effects than marijuana. Lack of information about the actual concentration of the substance on the packaging does not allow drug users to have an adequate dosage, with possible toxic consequences on health. Further investigations must be done to discover the true extent of the phenomenon.

Keywords: 5F-Cumyl-PINACA, synthetic cannabinoids, new psychoactive substances, legal high, MRM-IDA-EPI, LC-ESI-MS/MS, Che Sballo platinum, intoxication

« Previous Next »
Graphical Abstract

[1]
EMCDDA. Synthetic cannabinoids in Europe - update 2017; Perspect on Drugs, Lisbon 2017, 9. Available from: http://www.emcdda.europa.eu/publications/pods/synthetic-cannabinoids_en
[2]
Castaneto, M.S.; Gorelick, D.A.; Desrosiers, N.A.; Hartman, R.L.; Pirard, S.; Huestis, M.A. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend., 2014, 144(1), 12-41.
[http://dx.doi.org/10.1016/j.drugalcdep.2014.08.005] [PMID: 25220897]
[3]
World Health Orgainization. Expert Committee on Drug Dependence. 40th Review Report. Geneva, Switzerland, 21–25 October 2019. pp. 1-44. Available from, https://apps.who.int/iris/ bitstream/handle/10665/279948/9789241210225-eng.pdf
[4]
Fattore, L.; Fratta, W. Beyond THC: The new generation of cannabinoid designer drugs. Front. Behav. Neurosci., 2011, 5(9), 60.
[http://dx.doi.org/10.3389/fnbeh.2011.00060] [PMID: 22007163]
[5]
Diao, X.; Huestis, M.A. Approaches, challenges, and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites. Clin. Pharmacol. Ther., 2017, 101(2), 239-253.
[http://dx.doi.org/10.1002/cpt.534] [PMID: 27727455]
[6]
EMCDDA. Synthetic cannabinoids in Europe – a review. Lisbon, Portugal 2021, 1249-1289. Available from: http://www. emcdda.europa.eu/system/files/publications/14035/Synthetic-cannabinoids-in-Europe-EMCDDA-technical-report.pdf
[7]
Harris, C.R.; Brown, A. Synthetic cannabinoid intoxication: A case series and review. J. Emerg. Med., 2013, 44(2), 360-366.
[http://dx.doi.org/10.1016/j.jemermed.2012.07.061] [PMID: 22989695]
[8]
Labay, L.M.; Caruso, J.L.; Gilson, T.P.; Phipps, R.J.; Knight, L.D.; Lemos, N.P.; McIntyre, I.M.; Stoppacher, R.; Tormos, L.M.; Wiens, A.L.; Williams, E.; Logan, B.K. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci. Int., 2016, 260, 31-39.
[http://dx.doi.org/10.1016/j.forsciint.2015.12.046] [PMID: 26795398]
[9]
Kraemer, M.; Boehmer, A.; Madea, B.; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 2019, 298, 186-267.
[http://dx.doi.org/10.1016/j.forsciint.2019.02.021] [PMID: 30925344]
[10]
Behonick, G.; Shanks, K.G.; Firchau, D.J.; Mathur, G.; Lynch, C.F.; Nashelsky, M.; Jaskierny, D.J.; Meroueh, C. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J. Anal. Toxicol., 2014, 38(8), 559-562.
[http://dx.doi.org/10.1093/jat/bku048] [PMID: 24876364]
[11]
Gerostamoulos, D.; Drummer, O.H.; Woodford, N.W. Deaths linked to synthetic cannabinoids. Forensic Sci. Med. Pathol., 2015, 11(3), 478-478.
[http://dx.doi.org/10.1007/s12024-015-9669-5] [PMID: 25772119]
[12]
Angerer, V.; Franz, F.; Moosmann, B.; Bisel, P.; Auwärter, V. 5F-Cumyl-PINACA in ‘e-liquids’ for electronic cigarettes: Comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicol., 2019, 37(1), 186-196.
[http://dx.doi.org/10.1007/s11419-018-0451-8] [PMID: 30636986]
[13]
Staeheli, S.N.; Poetzsch, M.; Veloso, V.P.; Bovens, M.; Bissig, C.; Steuer, A.E.; Kraemer, T. In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA. Drug Test. Anal., 2018, 10(1), 148-157.
[http://dx.doi.org/10.1002/dta.2298] [PMID: 28885775]
[14]
Haschimi, B.; Grafinger, K.E.; Pulver, B.; Psychou, E.; Halter, S.; Huppertz, L.M.; Westphal, F.; Pütz, M.; Auwärter, V. New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA. Drug Test. Anal., 2021, 13(8), 1499-1515.
[http://dx.doi.org/10.1002/dta.3038] [PMID: 33788409]
[15]
Bovens, M.; Bissig, C.; Staeheli, S.N.; Poetzsch, M.; Pfeiffer, B.; Kraemer, T. Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA. Forensic Sci. Int., 2017, 281, 98-105.
[http://dx.doi.org/10.1016/j.forsciint.2017.10.020] [PMID: 29125990]
[16]
Alves, V.L.; Gonçalves, J.L.; Aguiar, J.; Teixeira, H.M.; Câmara, J.S. The synthetic cannabinoids phenomenon: From structure to toxicological properties. A review. Crit. Rev. Toxicol., 2020, 50(5), 359-382.
[http://dx.doi.org/10.1080/10408444.2020.1762539] [PMID: 32530350]
[17]
Gaunitz, F.; Andresen-Streichert, H. Analytical findings in a non-fatal intoxication with the synthetic cannabinoid 5F-ADB (5F-MDMB-PINACA): A case report. Int. J. Legal Med., 2022, 136(2), 577-589.
[http://dx.doi.org/10.1007/s00414-021-02717-6] [PMID: 34921326]
[18]
Gamage, T.F.; Farquhar, C.E.; McKinnie, R.J.; Kevin, R.C.; McGregor, I.S.; Trudell, M.L.; Wiley, J.L.; Thomas, B.F. Synthetic cannabinoid hydroxypentyl metabolites retain efficacy at human cannabinoid receptors. J. Pharmacol. Exp. Ther., 2019, 368(3), 414-422.
[http://dx.doi.org/10.1124/jpet.118.254425] [PMID: 30552295]
[19]
Chimalakonda, K.C.; Seely, K.A.; Bratton, S.M.; Brents, L.K.; Moran, C.L.; Endres, G.W.; James, L.P.; Hollenberg, P.F.; Prather, P.L.; Radominska-Pandya, A.; Moran, J.H. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metab. Dispos., 2012, 40(11), 2174-2184.
[http://dx.doi.org/10.1124/dmd.112.047530] [PMID: 22904561]
[20]
Fantegrossi, W.E.; Moran, J.H.; Radominska-Pandya, A.; Prather, P.L. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? Life Sci., 2014, 97(1), 45-54.
[http://dx.doi.org/10.1016/j.lfs.2013.09.017] [PMID: 24084047]
[21]
Tai, S.; Fantegrossi, W.E. Synthetic cannabinoids: Pharmacology, behavioral effects, and abuse potential. Curr. Addict. Rep., 2014, 1(2), 129-136.
[http://dx.doi.org/10.1007/s40429-014-0014-y] [PMID: 26413452]
[22]
Dobaja, M.; Grenc, D.; Kozelj, G.; Brvar, M. Occupational transdermal poisoning with synthetic cannabinoid cumyl-PINACA. Clin. Toxicol., 2017, 55(3), 193-195.
[http://dx.doi.org/10.1080/15563650.2016.1278224] [PMID: 28084855]
[23]
Kevin, R.C.; Anderson, L.; McGregor, I.S.; Boyd, R.; Manning, J.J.; Glass, M.; Connor, M.; Banister, S.D. CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Front. Pharmacol., 2019, 10(MAY), 595.
[http://dx.doi.org/10.3389/fphar.2019.00595] [PMID: 31191320]
[24]
Hermanns-Clausen, M.; Kneisel, S.; Szabo, B.; Auwärter, V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction, 2013, 108(3), 534-544.
[http://dx.doi.org/10.1111/j.1360-0443.2012.04078.x] [PMID: 22971158]
[25]
Hermanns-Clausen, M.; Kithinji, J.; Spehl, M.; Angerer, V.; Franz, F.; Eyer, F.; Auwärter, V. Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project. Drug Test. Anal., 2016, 8(10), 1030-1038.
[http://dx.doi.org/10.1002/dta.1936] [PMID: 26768345]
[26]
Freeman, W.D.; Louh, I.K.; Gooch, C.L.; Freeman, M.J.; Rose, D.Z.; Burgin, W.S. Ischemic stroke after use of the synthetic marijuana “spice”. Neurology, 2014, 83(8), 772-773.
[http://dx.doi.org/10.1212/01.wnl.0000453555.25241.99] [PMID: 25135913]
[27]
Radaelli, D.; Manfredi, A.; Zanon, M.; Fattorini, P.; Scopetti, M.; Neri, M.; Frisoni, P.; D’Errico, S. Synthetic cannabinoids and cathinones cardiotoxicity: Facts and perspectives. Curr. Neuropharmacol., 2021, 19(11), 2038-2048.
[http://dx.doi.org/10.2174/1570159X19666210412101929] [PMID: 33845747]
[28]
Centers for Disease Control and Prevention (CDC) Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb. Mortal. Wkly. Rep., 2013, 62(6), 93-98.
[PMID: 23407124]
[29]
Tait, R.J.; Caldicott, D.; Mountain, D.; Hill, S.L.; Lenton, S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin. Toxicol., 2016, 54(1), 1-13.
[http://dx.doi.org/10.3109/15563650.2015.1110590] [PMID: 26567470]
[30]
Luethi, D.; Liechti, M.E. Designer drugs: Mechanism of action and adverse effects. Arch. Toxicol., 2020, 94(4), 1085-1133.
[http://dx.doi.org/10.1007/s00204-020-02693-7] [PMID: 32249347]
[31]
Lindigkeit, R.; Boehme, A.; Eiserloh, I.; Luebbecke, M.; Wiggermann, M.; Ernst, L.; Beuerle, T. Spice: A never ending story? Forensic Sci. Int., 2009, 191(1-3), 58-63.
[http://dx.doi.org/10.1016/j.forsciint.2009.06.008] [PMID: 19589652]
[32]
EMCADA. European Report on Drugs; , 2018. Available from: https://www.emcdda.europa.eu/system/files/publications/13238/TD0420439ITN.pdf
[33]
Presidency of the Council of Minister, Department of Drug Policy. Annual report of parliament of the phenomenon of drug addiction in Italy. 2022. Available from: https://www.politicheantidroga. gov.it/media/3404/relazione-al-parlamento-2022.pdf
[34]
ESPAD Group. ESPAD Report: Results from the European School Survey Project on Alcohol and Other Drugs 2019, 1-136. Available from: http://www.espad.org/sites/espad.org/files/2020. 3878_EN_04.pdf
[35]
ESPAD Italia. 2021. Available from:. https://www.espad.it/ (Accessed on: 2022 Mar 23)
[36]
Osservatorio sulle dipendenze della regione Friuli Venezia Giulia Rapporto 2020; Consumo, dipendenza da sostanze e comportamenti di addiction in Friuli Venezia Giulia, 2020. Available from: http://www.welfare.fvg.it/images/Dipendenze/Report-NIOD-FVG-2020.pdf
[37]
Banister, S.D.; Adams, A.; Kevin, R.C.; Macdonald, C.; Glass, M.; Boyd, R.; Connor, M.; McGregor, I.S.; Havel, C.M.; Bright, S.J.; Vilamala, M.V.; Lladanosa, C.G.; Barratt, M.J.; Gerona, R.R. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Test. Anal., 2019, 11(2), 279-291.
[http://dx.doi.org/10.1002/dta.2491] [PMID: 30151911]
[38]
Longworth, M.; Banister, S.D.; Boyd, R.; Kevin, R.C.; Connor, M.; McGregor, I.S.; Kassiou, M. Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. ACS Chem. Neurosci., 2017, 8(10), 2159-2167.
[http://dx.doi.org/10.1021/acschemneuro.7b00267] [PMID: 28792725]
[39]
Abouchedid, R.; Hudson, S.; Thurtle, N.; Yamamoto, T.; Ho, J.H.; Bailey, G.; Wood, M.; Sadones, N.; Stove, C.P.; Dines, A.; Archer, J.R.H.; Wood, D.M.; Dargan, P.I. Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015. Clin. Toxicol., 2017, 55(5), 338-345.
[http://dx.doi.org/10.1080/15563650.2017.1287373] [PMID: 28421836]
[40]
Monte, A.A.; Bronstein, A.C.; Cao, D.J.; Heard, K.J.; Hoppe, J.A.; Hoyte, C.O.; Iwanicki, J.L.; Lavonas, E.J. An outbreak of exposure to a novel synthetic cannabinoid. N. Engl. J. Med., 2014, 370(4), 389-390.
[http://dx.doi.org/10.1056/NEJMc1313655] [PMID: 24450915]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy